Zai Lab gets China review for Pfizer-partnered cervical cancer therapy

koto_feja Zai Lab Limited ( NASDAQ: ZLAB ) announced Thursday that Chinese regulators accepted its marketing application for the cervical cancer therapy Tivdak developed in partnership with Pfizer ( NYSE: PFE ) unit Seagen. The company had submitted a Biologics License Application (BLA) for Tivdak with China’s National Medical.